QIAGEN
About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. The company employs more than 3,100 people in over 30 locations worldwide. QIAGEN’s North American headquarters is in Germantown, Maryland and its global headquarters is located in Hilden, Germany.
Further information about QIAGEN can be found at http://www.qiagen.com/.
123 articles about QIAGEN
-
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
7/27/2022
QIAGEN announced a series of enhancements for its QIAcuity series of digital PCR instruments designed to drive greater use among customers, particularly those involved in the biopharma industry: New solutions are now available with ten new QIAcuity Cell and Gene Therapy dPCR Assays for use in adeno-associated virus titer quantification and three new QIAcuity Residual DNA Quantification Kits for checking carryover of host cell DNA.
-
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
7/26/2022
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter of 2022 and increased the outlook for full-year 2022.
-
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
7/19/2022
QIAGEN Clinical Insights platform growing at over 35% annually, or 700,000 additional cases, and recently breaking through three million cases analyzed and reported.
-
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.
-
ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN
4/4/2022
ATCC, the world’s premier biological materials management and standards organization, announced that it has entered into an agreement with QIAGEN, a recognized leader in bioinformatics solutions, to provide them with sequencing data from its collection of cell lines, and animal and human biological materials.
-
Singular Genomics Partners with QIAGEN to Enable QIAseq Kits for the G4 Sequencing Platform
2/28/2022
Singular Genomics Systems, Inc. today announced a partnership with QIAGEN to validate its QIAseq kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform.
-
Element Biosciences Partners with QIAGEN to Validate a Selection of QIAseq Targeted Library Construction Chemistries on Element’s AVITI™ System
2/22/2022
Element Biosciences, Inc. today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings on the AVITI System.
-
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
2/8/2022
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the fourth quarter and full-year 2021.
-
QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
12/9/2021
QIAGEN and Denovo Biopharma LLC announced a collaboration to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 who are likely to respond to Denovo’s investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma, one of the most common lymphoid cancers.
-
Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
12/9/2021
Denovo Biopharma LLC and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1™) who are likely to respond to Denovo's investigational cancer drug DB102™ for treatment of diffuse large B-cell lymphoma (DLBCL), one of the most common lymphoid cancers.
-
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
11/29/2021
QIAGEN and DiaSorin announced that the U.S. Food and Drug Administration has approved the LIAISON® QuantiFERON®-TB Gold Plus assay for use on DiaSorin’s automated LIAISON® XS platform.
-
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
11/2/2021
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE-marking of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2.
-
QIAGEN Strengthens UK Footprint With Move to New Manchester Facilities
10/22/2021
QIAGEN today announced the completion of the move of its European Center of Excellence for Precision Medicine into facilities in Manchester’s CityLabs 2.0, a new genomics campus developed with Health Innovation Manchester.
-
QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements
8/9/2021
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
-
QIAGEN receives U.S. FDA emergency use authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
8/6/2021
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its QIAreach® SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results.
-
QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology
7/1/2021
QIAGEN announced a global strategic alliance with Japan’s Sysmex Corporation for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing.
-
Statement from Davidson Kempner regarding Qiagen
6/30/2021
Qiagen's Supervisory Board suffers from a lack of trust and confidence due to its history of ineffectiveness and governance concerns. This has created a credibility issue that is currently reflected in Qiagen's steep valuation discount to peers and its own historic multiples, and negatively impacts the business.
-
The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.
-
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
6/21/2021
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.
-
QIAGEN Launches artus Prep as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity
4/20/2021
QIAGEN’s innovative technology integrates sample preparation and detection in a single kit, enabling throughput of more than 670 tests per PCR cycler in an eight-hour shift